NewslettersHematopoiesis NewsUncategorizedEfficacy of Venetoclax plus Rituximab for Relapsed CLL: 5-Year Follow-Up of Continuous or Limited- Duration TherapyBy Justin.choi - September 14, 202108The authors reported long-term follow-up of the Phase Ib study of venetoclax and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL), including outcomes with continuous or limited-duration therapy.[Blood] 7992332 {7992332:BBBBBBBB} apa 50 1 166727 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/Full ArticleGraphical Abstract